As of March 18, 2026, public perception of Lyumjev 100 units/mL pen injection remains focused on its utility as a rapid-acting insulin therapy for managing glycemic control. The most significant recent development involves the expansion of its FDA-approved label to include administration via insulin pumps, a milestone reported in mid-March 2026 that has been framed by medical professionals as a meaningful advancement for patients struggling with post-meal blood sugar spikes.